Influenza Virus Vaccine for the 2016-2017 Season
Cumulative 2016/2017 Season Lot Release Status (Updated 12/7/2016)
Flu vaccine lots that have been released by FDA and are available for distribution by the manufacturers. For information on flu vaccine distribution schedules, please contact the manufacturers directly.
|Manufacturer||Total Number of Lots Released by FDA|
|Afluria - Seqirus Pty. Ltd.||55|
|Afluria Quadrivalent - Seqirus Pty. Ltd.||1|
|Fluad - Seqirus, Inc.||10|
|Fluarix Quadrivalent - GlaxoSmithKline Biologicals||52|
|Flublok - Protein Sciences Corporation||6|
|Flublok Quadrivalent - Protein Sciences Corporation||0|
|Flucelvax Quadrivalent - Seqirus, Inc.||21|
|FluLaval Quadrivalent - ID Biomedical Corporation of Quebec||23|
|FluMist Quadrivalent - MedImmune, LLC||12|
|Fluvirin - Seqirus Vaccines Limited||33|
|Fluzone High Dose - Sanofi Pasteur, Inc.||27|
|Fluzone Quadrivalent - Sanofi Pasteur, Inc.||47|
FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Silver Spring, Maryland, on March 4, 2016, to select the influenza viruses for the composition of the influenza vaccine for the 2016-2017 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2015-2016 vaccines, and the availability of candidate strains and reagents.
The committee recommended that the trivalent formulation influenza vaccines for the U.S. 2016-2017 influenza season contain the following:
- an A/California/7/2009 (H1N1)-like virus;
- an A/Hong Kong /4801/2014 (H3N2)-like virus
- a B/Brisbane/60/2008-like virus (B/Victoria lineage).
The committee also recommended that quadrivalent influenza vaccines contain the above three strains and the following additional B strain:
- a B/Phuket/3073/2013-like virus (B/Yamagata lineage)